⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799528 | 0.81 | — | — | |
| SCHEMBL359530 | 0.81 | — | — | |
| SCHEMBL771083 | 0.81 | — | — | |
| SCHEMBL25675163 | 0.79 | ADH1B (0.38) | — | |
| SCHEMBL3939409 | 0.78 | ADH1B (0.52) | — | |
| SCHEMBL12853734 | 0.77 | ADH1B (0.36) | — | |
| SCHEMBL769923 | 0.75 | ADH1B (0.59) | — | |
| SCHEMBL24699312 | 0.74 | — | — | |
| SCHEMBL11896733 | 0.74 | — | — | |
| SCHEMBL21779839 | 0.73 | ADH1B (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556908-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-02-11 | — | — | US | claimed |
| US-20190106426-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-04-11 | — | — | US | claimed |
| US-10112950-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-10-30 | — | — | US | claimed |
| US-20170369497-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | claimed |
| US-9695180-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | claimed |
| US-20160009720-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | claimed |
| WO-2016007736-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | claimed |
| EP-3581576-B1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2022-01-26 | — | — | EP | disclosed |
| US-10556908-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| CN-110461835-A | Isoxazole benzamide compound and application thereof | NOVARTIS AG | 2019-11-15 | — | — | CN | disclosed |
| EP-3177617-B1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS LLC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190106426-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-04-11 | — | — | US | disclosed |
| CN-109134367-A | A kind of compound and application thereof inhibiting ROCK | 成都先导药物开发有限公司 | 2019-01-04 | — | — | CN | disclosed |
| US-10112950-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170369497-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | disclosed |
| US-9695180-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160009720-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2016007736-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| WO-2013120980-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |